Drugs / CD19CAR-TCM cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01475058 | Apr 2012 → Apr 2014 | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), adult acute lymphoblastic leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma +2 | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19CAR-TCM cells | “Allogeneic CD19-specific chimeric antigen receptor-modified CD8+ central memory derived virus-specific T cells. Allogeneic CD19CAR-TCM cells given IV” NCT01475058 ↗ |
| Modality | Cell therapy | “adoptive T cell therapy” NCT01475058 ↗ |
| Route | Intravenous | “Allogeneic CD19CAR-TCM cells given IV” NCT01475058 ↗ |
| Target | CD19 | “CAR targeting CD19” NCT01475058 ↗ |